(TheNewswire)
Vancouver, British Columbia / TheNewswire / BioMark Diagnostics Inc.
(“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for
SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed
journal Future Science OA.
Rashid Ahmed, President and CEO, says, “This is our follow up publication and we would like to acknowledge the
contributions made by a dedicated team of clinicians, scientists and researchers. This publication provides further scientific
validation and evidence that one of our technology platforms (SSAT1 assay) has important clinical applications in the cancer
diagnostic space. We believe that the SSAT1 assay platform is robust and can be leveraged to detect other cancer types. Potential
utility of the assay includes being used as a surveillance test in populations at high risk for developing cancer and for
monitoring patients after surgical or chemo/radiation therapy to detect not only the response of the tumor to the intervention, but
also the possibility to detect the proliferation of new cancer cells.”
“BioMark is looking forward to publishing additional peer reviewed papers and
present abstracts or posters in the near term on significant discoveries that it has invested resources over the past few years.”
says Rashid.
The paper is available through open access at https://www.future-science.com/doi/full/10.4155/fsoa-2018-0106. BioMark encourages
subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in
biotechnology and medicine.
About Future Science OA
Future Science and Newlands Press, imprints of Future Science Group, focus on applied science and intellectual
property issues in R&D. The journals and eBooks take readers through the pharmaceutical R&D pipeline – from drug discovery,
delivery, pharmacokinetics and analytical techniques, through to commentary and analysis on patent and IP issues. The flagship gold
open access journal, Future Science OA, also embraces the importance of publishing all
good-quality research, and covers all areas of biotechnology and medicine, as well as topics in biological, life and physical
sciences that are of relevance to human health.
Future Science Journals
Future Science journals provide research professionals worldwide with a unique source of objective cutting-edge
information on the most exciting emerging trends in their field of endeavour.
Access to publications is possible via print and online subscriptions or via pay-per-view purchase via the website (for
more information, see Subscriptions
and Pricing).
Contact:
Laura Dormer, Editorial
Director
Future Science Group,
Unitec House,
2 Albert Place,
London,
N3 1QB, UK
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help
detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response
to treatment and potentially for serial monitoring for cancer survivors.
Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation,
concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by
the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking
information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can
give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the
date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether
as a result of new information, future events or results or otherwise, other than as required by applicable securities
laws.
The CSE has not reviewed, approved or disapproved the content of this press release.
Copyright (c) 2019 TheNewswire - All rights reserved.